Analysis of Failure After Curative Irradiation of Extrahepatic Bile Duct Carcinoma
THE INTEGRATION OF CHEMOTHERAPY THE INTEGRATION OF CHEMOTHERAPY IN CURATIVE TREATMENT OF HEAD AND IN...
Transcript of THE INTEGRATION OF CHEMOTHERAPY THE INTEGRATION OF CHEMOTHERAPY IN CURATIVE TREATMENT OF HEAD AND IN...
THE INTEGRATION OF CHEMOTHERAPY THE INTEGRATION OF CHEMOTHERAPY IN CURATIVE TREATMENT OF HEAD AND IN CURATIVE TREATMENT OF HEAD AND
NECK CANCER:NECK CANCER:
Marshall Posner, MDMarshall Posner, MDDanaDana--Farber Cancer InstituteFarber Cancer Institute
Biologic Principles, Changing Paradigms, Biologic Principles, Changing Paradigms, and New Therapies for 2009and New Therapies for 2009
Chemotherapy Is Part Of An Integrated Chemotherapy Is Part Of An Integrated Combined Modality Treatment PlanCombined Modality Treatment Plan
Multidisciplinary ClinicMultidisciplinary Clinic–– Determine the Stage/ExtentDetermine the Stage/Extent
»» Establish Prognostic/Predictive FactorsEstablish Prognostic/Predictive Factors
–– Establish and Coordinate the Treatment PlanEstablish and Coordinate the Treatment Plan»» Prepare the PatientPrepare the Patient
–– Monitor Response and ToxicityMonitor Response and Toxicity»» Modify Therapy Based on Response/PrognosisModify Therapy Based on Response/Prognosis
–– Long Term Follow Up for Toxicity, Recurrence Long Term Follow Up for Toxicity, Recurrence and Second Primaryand Second Primary
SCCHN Differs from Many Other Tumor SitesSCCHN Differs from Many Other Tumor Sites–– The Structures of the Head and Neck are Constantly FunctioningThe Structures of the Head and Neck are Constantly Functioning–– Patients Can Spend a Year or More to Reasonable RecoveryPatients Can Spend a Year or More to Reasonable Recovery
Morbidity Can be Significant and ProlongedMorbidity Can be Significant and Prolonged–– ChemotherapyChemotherapy
»» Mucositis, Neutropenia, Nausea/Vomiting, Neuropathy Mucositis, Neutropenia, Nausea/Vomiting, Neuropathy –– Radiotherapy and ChemoradiotherapyRadiotherapy and Chemoradiotherapy
»» Pain, Mucositis, Esophageal Stenosis, Muscular Dysfunction, Pain, Mucositis, Esophageal Stenosis, Muscular Dysfunction, Scarring/Fibrosis, Dry Mouth, Carotid Stenosis, Radiation InduceScarring/Fibrosis, Dry Mouth, Carotid Stenosis, Radiation Induced d Second CancersSecond Cancers
–– SurgerySurgery»» Impaired Swallowing, Breathing and Speech, Shoulder Dysfunction Impaired Swallowing, Breathing and Speech, Shoulder Dysfunction
Therapy is IntensiveTherapy is Intensive–– A Coordinated Team Approach is Vital for SuccessA Coordinated Team Approach is Vital for Success
»» Nursing is Critical During Aggressive Chemotherapy and Nursing is Critical During Aggressive Chemotherapy and ChemoradiotherapyChemoradiotherapy
»» Hydration; Pain and Symptom Management; Swallowing Therapy; Hydration; Pain and Symptom Management; Swallowing Therapy; Psychosocial SupportPsychosocial Support
Head and Neck Cancer: Head and Neck Cancer: Morbidity of TreatmentMorbidity of Treatment
Chemoradiotherapy Induced Mucositis
What Do Patients Want?What Do Patients Want?
List MA, et al. Head Neck. 2004; 26(2):163-170.
Cited Among Top 3 PrioritiesCited Among Top 3 Priorities
Factors Important in Determining the Factors Important in Determining the Intensity of Treatment and Organ PreservationIntensity of Treatment and Organ Preservation
PatientPatient»» Age, Fragility, Rehab PotentialAge, Fragility, Rehab Potential»» Psychosocial Issues Psychosocial Issues --Compliance, Addictions, MotivationCompliance, Addictions, Motivation»» CoCo--Morbid IllnessesMorbid Illnesses-- Modifications of TherapyModifications of Therapy»» Performance StatusPerformance Status
TumorTumor»» Location Location -- Anterior Lesions Anterior Lesions -- Oropharynx, Larynx, HypopharynxOropharynx, Larynx, Hypopharynx--
Nasopharynx, Posterior pharynxNasopharynx, Posterior pharynx»» Biology Biology -- Growth RateGrowth Rate»» Stage Stage -- N2/N3N2/N3»» HPV StatusHPV Status
GoalsGoals»» Organ Preservation, Survival, Distant MetastasesOrgan Preservation, Survival, Distant Metastases
HearHear No Induction No Induction SeeSee No InductionNo Induction
SpeakSpeak No InductionNo Induction
INDUCTION APHASIAINDUCTION APHASIA
Effects of Chemotherapy on Survival at 5 Years:Effects of Chemotherapy on Survival at 5 Years:From the MetaFrom the Meta--AnalysisAnalysis
Trial CategoryTrial Category No. of TrialsNo. of Trials No. PatientsNo. Patients Difference(%)Difference(%) PP valuevalueAll trialsAll trials 6565 1085010850 +4+4 <0.0001<0.0001AdjuvantAdjuvant 88 18541854 +1+1 0.740.74InductionInduction 3131 52695269 +2+2 0.100.10PFPF 1515 24872487 +5+5 0.010.01Other ChemoOther Chemo 1616 27822782 00 0.910.91ConcomitantConcomitant 2626 37273727 +8+8 <0.0001<0.0001
Monnerat, et al. Annals of Oncology, 13: 995-1006, 2002.
The STUDIO Induction Chemotherapy Trial:The STUDIO Induction Chemotherapy Trial:A Phase III Study of PF Induction ChemotherapyA Phase III Study of PF Induction Chemotherapy
RANDOMIZE
P
F
Radiotherapy4 Cycles of Chemotherapy
Surgery
No Surgery
Radiotherapy
Surgery
Radiotherapy
STRATIFY
No Chemotherapy
Chemotherapy
No Surgery(-) Biopsy
Nodal Surgery
(-) Biopsy
Nodal Surgery
Paccagnella A, et al. J Natl Cancer Inst. 1994;86:265-272
Studio Induction Chemotherapy Trial: Studio Induction Chemotherapy Trial: Overall Survival for Operable PatientsOverall Survival for Operable Patients
A group, initial chemotherapy (cisplatin and infusional fluorouracil) followed by locoregional treatment (n=118).B group, locoregional treatment alone (n=119).Paccagnella A, et al. J Natl Cancer Inst. 1994;86:265-272.
0
0.5
1
0 12 24 36 48
A groupB group
Months from randomization
Ove
rall
surv
ival 27
1915
106
60
28
19
14 9 6
•• Conclusion: postConclusion: post--CT surgery did CT surgery did not improve survival in operable not improve survival in operable patientspatients−− Surgery may Surgery may ↑↑ risk of localrisk of local--
regional recurrenceregional recurrence−− Surgical Margins InadequateSurgical Margins Inadequate−− Tumor repopulation and Tumor repopulation and
resistance enhanced by resistance enhanced by delay to XRTdelay to XRT
−− Lack of primary site Lack of primary site preservationpreservation
Studio Induction Chemotherapy Trial: Studio Induction Chemotherapy Trial: Overall Survival for Inoperable Patients Overall Survival for Inoperable Patients –– 10 Year Data10 Year Data
PF group, initial chemotherapy (cisplatin and infusional fluorouracil) followed by locoregional treatment (n=118).XRT group, locoregional treatment alone (n=119).Zorat, P. L. et al. J Natl Cancer Inst 2004
•• ConclusionConclusion
−− PF Induction Chemotherapy PF Induction Chemotherapy Improves Survival In Improves Survival In Patients With Unresectable Patients With Unresectable DiseaseDisease
−− LocalLocal--Regional FailureRegional Failure and and Distant Metastases were Distant Metastases were Reduced by PFReduced by PF0
20
40
60
80
100
0 20 40 60 80 100 120
SUR
VIVA
L (%
)
MONTHS
XRT
PF
Domenge C, et al. Br J Cancer. 2000;83:1594-1598.
Patients at risk
Overall Survival Oropharynx: Overall Survival Oropharynx: GETTECGETTEC
161157
137138
101105
6586
4859
2833
1619
77
Perc
ent
YearsNo chemotherapy Chemotherapy
0
40
20
60
80
100
0 1 2 3 4 5 6 7 8
BIOLOGICAL ASSUMPTIONS OF BIOLOGICAL ASSUMPTIONS OF CHEMORADIOTHERAPYCHEMORADIOTHERAPY
SCCHN is a Local Regional DiseaseSCCHN is a Local Regional DiseaseLocal Regional Failure Became the Dominant Local Regional Failure Became the Dominant
Concern Concern LocalLocal--Regional Control Regional Control --Persistent DiseasePersistent Disease
LocalLocal--Regional Control Regional Control --Recurrent DiseaseRecurrent Disease
LocalLocal--Regional Control Regional Control --New DiseaseNew Disease
Distant DiseaseDistant Disease
BIOLOGICAL ASSUMPTIONS OF BIOLOGICAL ASSUMPTIONS OF CHEMORADIOTHERAPYCHEMORADIOTHERAPY
Which Mechanism is Active?Which Mechanism is Active?–– Direct AntiDirect Anti--Tumor ActivityTumor Activity–– Radiation Sensitizing EffectRadiation Sensitizing Effect–– Combined EffectsCombined Effects
Which Mechanism is Desired?Which Mechanism is Desired?–– For Local/Regional TreatmentFor Local/Regional Treatment–– For Systemic TreatmentFor Systemic Treatment
How is Toxicity Effected?How is Toxicity Effected?–– Local/Regional ToxicityLocal/Regional Toxicity
»» SHORT TERM SHORT TERM vsvs LONG TERMLONG TERM–– Systemic ToxicitySystemic Toxicity
CHEMORADIOTHERAPY INCREASES LOCAL REGIONAL CONTROL BY INCREASING LOCAL-REGIONAL DOSE
INTENSITY
Calais Chemoradiotherapy Regimen: Calais Chemoradiotherapy Regimen: OropharynxOropharynx
1 2 3 4Weeks
Carboplatinum 70 mg/M2 /day x 4 days
QD RADIOTHERAPY200 cGy/ Fx
5-FU 600 mg/M2/days x 4 days
5 60 7
J Natl Cancer Inst. 1999;91:2081-2086.
Denis, F et al. JCO. 2004.
Calais Chemoradiotherapy Study:Calais Chemoradiotherapy Study:5 Year Survival 5 Year Survival
•• Conclusions:Conclusions:
−− Borderline statistically Borderline statistically significant (p = .05) better significant (p = .05) better overall survival with CRT overall survival with CRT (22% (22% vsvs 16%)16%)
−− Absolute 6% ImprovementAbsolute 6% Improvement
−− Better LRC (48% Better LRC (48% vsvs 25%), 25%), No Change in DM (20%)No Change in DM (20%)
−− CRT is Better then XRT CRT is Better then XRT alone for Oropharynx alone for Oropharynx CancerCancer
0
20
40
60
80
100
0 6 12 18 24 30 36 42 48 54 60 66 72
SUR
VIVA
L (%
)
MONTHS
CRT
XRT
A Phase III Trial of Chemoradiotherapy and A Phase III Trial of Chemoradiotherapy and Concomitant Boost Radiotherapy in Locally Advanced Concomitant Boost Radiotherapy in Locally Advanced
SCCHN of the Oropharynx and HypopharynxSCCHN of the Oropharynx and Hypopharynx
RANDOMIZE
A
F
B
Staar , IJROBP, 2001; 50: 1161-1171
C
Concomitant Boost XRT
70 cGy
Carboplatinum 70 mg/M2/day x 5 days
5-FU 600 mg/M2/day x 5 days
Concomitant Boost XRT
70 cGy
A Phase III Trial of Chemoradiotherapy and A Phase III Trial of Chemoradiotherapy and Concomitant Boost RadiotherapyConcomitant Boost Radiotherapy
Boost Boost --XRTXRT CFCF--XRTXRTPatientsPatients 127127 113113T4T4 102 (80%)102 (80%) 91 (82%)91 (82%)N2 + N3N2 + N3 109 (85%) 109 (85%) 93 (82%)93 (82%)55--Year SurvivalYear Survival
OropharynxOropharynx 13% 13% 26%26% p < .008p < .008HypopharynxHypopharynx 22%22% 22%22%
Distant MetastasesDistant Metastases 19% 21%19% 21%Mucositis Mucositis >> Grade 3Grade 3 52%52% 68%68% p < .01p < .01Esophageal StenosisEsophageal Stenosis 25%25% 50% 50% (Survivors at 2 years)(Survivors at 2 years)
Staar , IJROBP, 2001; 50: 1161-1171, Semrau, IJROBP, 2006,
INTINT--026: A Phase III Trial of Chemoradiotherapy in 026: A Phase III Trial of Chemoradiotherapy in Unresectable PatientsUnresectable Patients
RANDOMIZE
A
P
P
XRT
F
B
C
XRT
XRTSurgery
Adelstein, et al: JCO, 2003; 21:92-98
INT INT --026026 -- Survival OutcomesSurvival Outcomes
AA BB CCXRTXRT PP--XRTXRT PFPF--SCSC--XRTXRT
Evaluable PatientsEvaluable Patients 9595 8787 8989Disease Specific (3 yr)Disease Specific (3 yr) 34% 34% 56%56%** 42%42%Overall Survival (3 yr)Overall Survival (3 yr) 23%23% 37%37%** 27%27%MedianMedian SurvivalSurvival 12.6 Mo12.6 Mo 19.1 Mo19.1 Mo 13.8 Mo13.8 MoRate of DMRate of DM 18% (30%) 22% (18% (30%) 22% (51%51%) 19% (29%) ) 19% (29%)
““Feeding TubeFeeding Tube”” 40%40% 52% 52% 51%51%Toxic DeathToxic Death 2%2% 4%4% 2%2%NonNon--Cancer DeathCancer Death 11%11% 19%19% 15%15%
* Significant Difference A vs B Adelstein, et al: JCO, 2003; 21:92-98
RTOG 91RTOG 91--1111Phase III Trial of Larynx PreservationPhase III Trial of Larynx Preservation
RANDOMIZE
A
P
P
XRT
F
B
C
XRT
XRT Surgery
+/- Surgery
Forastiere, NEJM, 2003
Forastiere, ASCO, 2006
547 ptsSt III/IV glottic,
supraglottic intermed. stage
+/- Surgery
Forastiere. ASCO. 2006LFS=laryngectomy-free survival
LFSLFS Overall SurvivalOverall Survival
RTOG 91RTOG 91--1111Phase III Trial of Larynx PreservationPhase III Trial of Larynx Preservation
PFPF CRTCRT XRTXRTLFSLFS 44.6%44.6% 46.6%46.6% 33.9% p < .01133.9% p < .011LRCLRC 54.9%*54.9%* 68.8%*68.8%* 51% p < .001851% p < .0018DMDM 14.3%14.3% 13.2%13.2% 22.3% p = .0622.3% p = .06DFSDFS 38.6%*38.6%* 39%39% 27.3%* p < .001627.3%* p < .0016Survival 59.2% 54.6% 53.5%Survival 59.2% 54.6% 53.5%
RTOG 91RTOG 91--11:Phase III Trial of Larynx 11:Phase III Trial of Larynx Preservation: ASCOPreservation: ASCO-- 55--Year UpdateYear Update
1.1. PF was PF was EquivalentEquivalent to CRT for LFS to CRT for LFS 2.2. CRT had Better LRC Than PFCRT had Better LRC Than PF3.3. DFS Was Identical But Overall Survival DFS Was Identical But Overall Survival
Favored PFFavored PF4.4. Did Patients Fare Better With PF Because Did Patients Fare Better With PF Because
They Had Subtle Improvements in Function They Had Subtle Improvements in Function Forastiere, ASCO, 2006
PF PF vsvs Alternating Chemoradiotherapy for Alternating Chemoradiotherapy for Resectable Larynx/Hypopharynx: Resectable Larynx/Hypopharynx: EORTCEORTC 2495424954
* P 100 mg/M2 plus 5FU 1000 mg/M2 D1* P 100 mg/M2 plus 5FU 1000 mg/M2 D1--55** P 20 mg/M2 D1** P 20 mg/M2 D1--5 plus 5FU 200 mg/M2 D15 plus 5FU 200 mg/M2 D1--55
RANDOMIZE
IND
P**
XRT
FALT
XRT
P*F
Lefebvre, JNCI, 2009
Survival with a Functional LarynxSurvival with a Functional Larynx
(years)
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk : Arm160 224 105 64 28 12154 226 117 73 39 18
SequentialAlternating
Overall Logrank test: p=0.155Hazard ratio 0.85 CI (0.68, 1.06)
Lefebvre, JNCI, 2009
Adjuvant ChemoradiotherapyAdjuvant Chemoradiotherapy
RANDOMIZE
CisplatinCisplatin100 mg/m100 mg/m22 d 1, 22, 43d 1, 22, 43
XRTXRT
XRT
Cooper , NEJM, 2004; 350: 1937 Bernier, NEJM, 2004;350:1945
SURGERY
RTOG 95RTOG 95--0101459 patients459 patients
EORTC 22931EORTC 22931334 patients334 patients
EORTC (66 Gy over 6 EORTC (66 Gy over 6 ½½ wks)wks)RTOG (60RTOG (60--66 Gy over 666 Gy over 6--6 6 ½½ wks)wks)
PostPost--Operative ChemoradiotherapyOperative Chemoradiotherapy
INT TrialINT TrialCRTCRT RTRT
AliveAlive 50%50% 41%41%LRFLRF 16%16% 29% *29% *DMDM 20%20% 23%23%
DM/FDM/F 60%60% 45%45%
EORTC Trial**EORTC Trial**CRTCRT RTRT
AliveAlive 53%53% 40% *40% *LRFLRF 18%18% 31% *31% *DMDM 21%21% 25%25%SPTSPT 12%12% 13%13%DM/FDM/F 54%54% 45%45%
* P < .05
Cooper , NEJM, 2004; 350: 1937 Bernier, NEJM, 2004;350:1945
**PNI, LVI
RTOG 01RTOG 01--29: A Randomized Phase III Trial of 29: A Randomized Phase III Trial of Chemoradiotherapy With Two SchedulesChemoradiotherapy With Two Schedules
RANDOMIZE
P - 100 mg/M2
XRT
XRT
P - 100 mg/M2
Trial Completed Accrual in 6/05
The Rate of Stomach Tube Dependence in the Phase III is ~16% at The Rate of Stomach Tube Dependence in the Phase III is ~16% at 2 years (Ang, ASTRO, 2007) 2 years (Ang, ASTRO, 2007)
The Cetuximab/Radiotherapy Phase III TrialThe Cetuximab/Radiotherapy Phase III Trial
RANDOMIZE
ERB
XRT
XRT
Surgery
Surgery
Bonner, NEJM, 2006
QD, BID or ACB Allowed
Stratify byKarnofsky score:90-100 vs. 60-80Regional Nodes:Negative vs. PositiveTumor stage:AJCC T1-3 vs. T4RT fractionation:Concomitant boostvs. Once dailyvs. Twice daily
The Cetuximab/Radiotherapy Phase The Cetuximab/Radiotherapy Phase III TrialIII Trial
RadiotherapyRadiotherapy BioRadiotherapyBioRadiotherapyToxicityToxicityMucositisMucositis 52%52% 54%54%RashRash 18%18% 34%34%Infusion ReactionsInfusion Reactions NANA 14%14%Late Peg DependencyLate Peg Dependency 17%17% 19%19%
EfficacyEfficacy33--Yr SurvivalYr Survival 44%44% 55%55%33--Yr LRCYr LRC 34%34% 47%47%22-- Yr DMYr DM 17%17% 16%16%DM/LRFDM/LRF 24%24% 30%30%
Bonner, NEJM, 2006; Bonner, Palm Springs, 2007
Overall Survival By Treatment: Overall Survival By Treatment: Median FollowMedian Follow--up 60 Monthsup 60 Months
31
1.01.00.90.90.80.80.70.70.60.60.50.50.40.40.30.30.20.20.10.10.00.0
00 1010 2020 3030 4040 5050 6060 7070Month
Ove
rall
Surv
ival
Stratified Logrank p = 0.018, HR=0.73 (0.56-0.95)
Treatment Total Death Alive Median
Radiation AloneRadiation Alone 213213 130130 8383 29.329.3RT + CetuximabRT + Cetuximab 211211 110110 101101 49.049.0
Bonner, ASTRO, 2008
Forest Plot of the Hazard Ratios by PreForest Plot of the Hazard Ratios by Pre--Treatment Treatment Characteristics Characteristics ––FiveFive--year Median Followyear Median Follow--upup
32
Bonner, ASTRO, 2008
Improvement With Cetuximab
****
* NS* NS
INDUCTION CHEMOTHERAPYINDUCTION CHEMOTHERAPY
ConsCons–– Systemic Toxicity Acute and Systemic Toxicity Acute and
IncreasedIncreased–– Survival Improvement may be Survival Improvement may be
Site and Stage RelatedSite and Stage Related–– Increased Duration of Therapy, Increased Duration of Therapy,
Change in Tumor BiologyChange in Tumor Biology–– No Improvement in No Improvement in
Local/Regional Dose IntensityLocal/Regional Dose Intensity–– CisplatinumCisplatinum--Based PF Based PF waswas the the
Only Effective Chemotherapy Only Effective Chemotherapy RegimenRegimen
ProsPros–– High Dose Treatment, Systemic Exposure, High Dose Treatment, Systemic Exposure,
Transient ToxicityTransient Toxicity–– Improved Nutrition and PSImproved Nutrition and PS–– Reduced Tumor VolumeReduced Tumor Volume
»» Better Preparation for Definitive Radiotherapy Better Preparation for Definitive Radiotherapy and IMRT Planningand IMRT Planning
»» Improved FunctionImproved Function–– Established Efficacy in Resectable Disease Established Efficacy in Resectable Disease
and Organ Preservationand Organ Preservation–– Improved Survival Improved Survival –– Intermediate Assessment of Intermediate Assessment of
Response/PrognosisResponse/Prognosis»» Adjusted Intensity of PostAdjusted Intensity of Post--Induction TherapyInduction Therapy
CHEMORADIOTHERAPYCHEMORADIOTHERAPY
ProsPros–– Improved Local Regional Improved Local Regional
IntensityIntensity–– Shortened Treatment TimeShortened Treatment Time–– Efficacy in Unresectable Efficacy in Unresectable
DiseaseDisease–– Efficacy in Organ PreservationEfficacy in Organ Preservation–– Effective PostEffective Post--Operative Operative
TherapyTherapy
ConsCons–– Local Toxicity Increased Local Toxicity Increased
»» Long Term Toxicity Not Defined and Long Term Toxicity Not Defined and LateLate
Esophageal Stenosis, Swallowing Esophageal Stenosis, Swallowing ImpairedImpairedLate Mortality from Unrecognized Late Mortality from Unrecognized ToxicityToxicity
»» Acute Severe Systemic ToxicityAcute Severe Systemic Toxicity–– Systemic Chemotherapy ResistanceSystemic Chemotherapy Resistance–– No Acceptable StandardNo Acceptable Standard–– Assessment of Response/Prognosis Assessment of Response/Prognosis
CompromisedCompromised–– No Effect on Distant Metastases in No Effect on Distant Metastases in
Advanced DiseaseAdvanced Disease–– IMRT Planning DifficultIMRT Planning Difficult
TAX 323TAX 323-- TPF TPF vsvs PF Followed by RadiotherapyPF Followed by RadiotherapyA Phase III Study in Unresectable SCCHNA Phase III Study in Unresectable SCCHN
RANDOMIZE
P
P
F
F
Daily Radiotherapy
EUA
T
Surgery
TPF: Docetaxel 75D1 + Cisplatin 75D1 + 5-FU 750 CI- D1-5 Q 3 weeks x4 PF: Cisplatin 100 D1 + 5-FU 1000 CI-D1-5 Q 3 weeks x 4
Vermorken NEJM, 2007
TN Stage of PrimaryTN Stage of Primary
StageStage T1T1 T2T2 T3T3 T4T4 TotalTotal
N0N0 1 (<1)1 (<1) 12 (3)12 (3) 29 (8)29 (8) 42 (12)42 (12)
N1N1 4 (1)4 (1) 13 (4)13 (4) 39 (11)39 (11) 56 (16)56 (16)
N2N2 1 (<1)1 (<1) 13 (4)13 (4) 38 (11)38 (11) 153 (43)153 (43) 205 (57)205 (57)
N3N3 3 (1)3 (1) 7 (2)7 (2) 11 (3)11 (3) 31 (9)31 (9) 52 (15)52 (15)
TotalTotal 4 (1)4 (1) 25 (7)25 (7) 77* (22)77* (22) 252 (70)252 (70) 358358* 3 patients were T3Nx
Vermoken, NEJM, 2007
TAX323 : SURVIVAL UPDATETAX323 : SURVIVAL UPDATE
Survival Time (months)
Sur
viva
l Pro
babi
lity
(%)
0 6 12 18 24 30 36 42 48 54 60 66 72
0
10
20
30
40
50
60
70
80
90
100
TPF (n=177)
PF (n=181)
Number of patients at riskTPF: PF:
177 163 127 91 74 64 60 43 26 16 7181 150 98 77 57 47 39 33 25 15 8 4
Log-Rank P = 0.0052 Hazard Ratio = 0.71
Vermorken, NEJM, 2007
Severe Adverse Events: ChemotherapySevere Adverse Events: ChemotherapyToxicity in PF (n=179) TPF (n=174)> 3% of pts N (%) N (%) Alopecia 0 20 (11.5)Stomatitis / oral 20 (11.2) 8 (4.6)Infection 13 (7.3) 15 (8.6)Nausea 13 (7.3) 1 (0.6)Vomiting 9 (5.0) 1 (0.6)Diarrhea 8 (4.5) 5 (2.9)Dyspnea 8 (4.5) 6 (3.4)Dysphagia 5 (2.8) 6 (3.4)Pain 7 (3.9) 11 (6.3)Death 12 (6.6) 6 (3.4)
Vermorken, NEJM, 2007
Can TPF Can TPF ImproveImprove OverallOverall SurvivalSurvival??
Zorat JNCI 2004
0.5
0.0
1.0
12010896847260483624120
Log-Rank = 4.04 ; p = .04
PF
RT
2013
11
469
An Analysis of Failure in Phase II An Analysis of Failure in Phase II TPF Induction Trials*TPF Induction Trials*
Trials:Trials: TPF, TPFL5, TPFL4, opTPF, TPFL5, TPFL4, op--TPFLTPFLEntered:Entered: 84* 84* Local/Regional Failure:Local/Regional Failure: 26 (31%)26 (31%)Local/Regional and DMLocal/Regional and DM 5 (6%)5 (6%)DM onlyDM only 00
*Excludes 17 Patients with NPC
Three Cycles of Induction Three Cycles of Induction TherapyTherapy Followed by:Followed by:BID RadiotherapyBID Radiotherapy
Haddad, Cancer, 2003
An Analysis of Failure in Phase III An Analysis of Failure in Phase III Chemoradiotherapy Trials*Chemoradiotherapy Trials*
Trials:Trials: INT EORTC RTOG GORTEC BonnerINT EORTC RTOG GORTEC BonnerLRFLRF 22% 18% 16% 57%22% 18% 16% 57% 53%53%DMDM 23% 21% 20% 18% 17%23% 21% 20% 18% 17%DM % of Failure DM % of Failure 51% 54% 65% 32% 30%51% 54% 65% 32% 30%RegimenRegimen BPBP BPBP BPBP CF ErbituxCF Erbitux
The Rate of DM Was The Rate of DM Was NotNot Generally Significantly Reduced by CRT*Generally Significantly Reduced by CRT*
*Larynx Trial 91-11 Came Close Adelstein, JCO, 2003; Bernier, NEJM, 2005; Cooper, NEJM, 2005; Denis, JCO, 2005; Bonner, NEJM, 2006
Sequential Therapy for Head and Neck Cancer:Sequential Therapy for Head and Neck Cancer:
Induction ChemotherapyInduction Chemotherapy
ChemoradiotherapyChemoradiotherapy
SurgerySurgery
Sequential Combined Modality TherapySequential Combined Modality TherapyA Phase III Study: TAX 324A Phase III Study: TAX 324
TPF TPF vsvs PF Followed by ChemoradiotherapyPF Followed by Chemoradiotherapy
RANDOMIZE
P
P
F
F
Carboplatinum - AUC 1.5 Weekly
Daily Radiotherapy
EUA
T
Surgery
TPF: Docetaxel 75D1 + Cisplatin 100D1 + 5-FU 1000 CI- D1-4 Q 3 weeks x3 PF: Cisplatin 100 D1 + 5-FU 1000 CI-D1-5 Q 3 weeks x 3
Posner, NEJM, 2007
TAX324: Patients Characteristics (ITT)TAX324: Patients Characteristics (ITT)TPF (N=255)TPF (N=255) PF (N=246)PF (N=246)
Age (years): Median (Range)Age (years): Median (Range)≥≥ 65 years65 years
55 (38 to 82)55 (38 to 82)34 (13%)34 (13%)
56 (33 to 80)56 (33 to 80)36 (15%)36 (15%)
Gender MaleGender Male 215 (84%)215 (84%) 204 (83%)204 (83%)
PS (WHO) 0PS (WHO) 011
142 (56%)142 (56%)113 (44%)113 (44%)
126 (51%)126 (51%)117 (48%)117 (48%)
Anatomic site OropharynxAnatomic site OropharynxLarynxLarynxHypopharynxHypopharynxOral cavityOral cavity
132 (52%)132 (52%)48 (19%)48 (19%)42 (17%)42 (17%)33 (13%)33 (13%)
131 (53%)131 (53%)42 (17%)42 (17%)34 (14%)34 (14%)38 (15%)38 (15%)
Clinical Stage IIIClinical Stage IIIIVIV
41 (16%)41 (16%)214 (84%)214 (84%)
46 (18%)46 (18%)199 (81%)199 (81%)
Reason InoperabilityReason InoperabilityTechnical UnresectabilityTechnical UnresectabilityLow Surgical CurabilityLow Surgical CurabilityOrgan PreservationOrgan Preservation
92 (36%)92 (36%)78 (31%)78 (31%)85 (33%)85 (33%)
84 (34%)84 (34%)75 (31%)75 (31%)87 (35%)87 (35%)
Survival Time (months)
Surv
ival
Pro
babi
lity
(%)
0 6 12 18 24 30 36 42 48 54 60 66 72
0
10
20
30
40
50
60
70
80
90
100
TPF (n=255)
PF (n=246)
Number of patients at riskTPF: PF:
255 234 196 176 163 136 105 72 52 45 37 20 11246 223 169 146 130 107 85 57 36 32 28 10 7
TAX324 : SurvivalTAX324 : Survival
TPF 62%
PF 48%
Log-Rank P = 0.0058 Hazard Ratio = 0.70
TPF 67%
PF 54%
TAX324: Toxicity During ChemotherapyTAX324: Toxicity During Chemotherapy
Number of PatientsNumber of Patients TPF (N=251)TPF (N=251) PF (N=243)PF (N=243)
NCICNCIC--CTG ClassificationCTG Classification Grade 3/4Grade 3/4 Grade 3/4Grade 3/4Any EventAny Event 65%65% 62%62%StomatitisStomatitisNauseaNauseaLethargyLethargyVomitingVomitingDiarrheaDiarrheaAnorexiaAnorexiaDeaths within 30 daysDeaths within 30 days
NonNon--Tumor RelatedTumor Related
21%21%14% 14% 5% 5% 8%8%7%7%
12% 12% 1.6%1.6%
27%27%14% 14% 10% 10% 10%10%3%3%
12%12%4.5%4.5%
TAX 324: Delays During Induction TAX 324: Delays During Induction ChemotherapyChemotherapy
TPF TPF --251251 PFPF--243243 All All --494494
Treatment Delay*Treatment Delay* 73 (29%)73 (29%) 157 (65%)157 (65%) 230 (47%)230 (47%)
HematologicHematologic 11 (4%)11 (4%) 108 (44%)108 (44%) 119 ( (24%)119 ( (24%)
NeutropeniaNeutropenia 2 (1%)2 (1%) 95 (39%)95 (39%) 97 (20%)97 (20%)
NonNon--HematologicHematologic 25 (10%)25 (10%) 22 (9.1%)22 (9.1%) 47 (10%)47 (10%)
Other** Other** 38 (15%)38 (15%) 40 (17%)40 (17%) 78 (16%)78 (16%)
** Logistic, Personal, Vacation *P < .0001
TAX 324: Analysis of FailureTAX 324: Analysis of FailureTPF TPF --251251 PF PF --243243 All All --494494
Total Failures/TreatedTotal Failures/Treated## 88 (35%)88 (35%) 110 (45%)110 (45%) 198 (40%)198 (40%)LRF*LRF* 77 (31%)77 (31%) 93 (38%)93 (38%) 170 (34%)170 (34%)PrimaryPrimary 43 (17%)43 (17%) 49 (20%)49 (20%) 92 (19%)92 (19%)
NeckNeck 22 (9%)22 (9%) 33 (14%)33 (14%) 55 (11%)55 (11%)BothBoth 12 (5%)12 (5%) 11 (5%)11 (5%) 23 (5%)23 (5%)
Distant Metastases**Distant Metastases** 14 (5%)14 (5%) 21 (9%)21 (9%) 35 (7%)35 (7%)Distant OnlyDistant Only 11 (4%)11 (4%) 17 (7%)17 (7%) 28 (6%)28 (6%)
Distant and LRFDistant and LRF 3 (1%)3 (1%) 4 (2%)4 (2%) 7 (1%)7 (1%)
Second PrimariesSecond Primaries 9 (4%)9 (4%) 7 (3%)7 (3%) 16 (3%)16 (3%)
# # Hazard Ratio .70 (0.53Hazard Ratio .70 (0.53--0.920.92)), P = .01 , P = .01 *Hazard Ratio 0.73 (0.54*Hazard Ratio 0.73 (0.54--0.99), P = .030.99), P = .03**Hazard Ratio 0.60 (0.30**Hazard Ratio 0.60 (0.30--1.18), P = .181.18), P = .18
GORTEC Phase III Trial of TPF GORTEC Phase III Trial of TPF vsvs PF Followed by PF Followed by Radiotherapy for Radiotherapy for Organ PreservationOrgan Preservation in in
ResectableResectable Larynx and Hypopharynx CancerLarynx and Hypopharynx Cancer
RANDOMIZE
P
P
F
F Daily Radiotherapy: STD or ACB
Response
T
TPF: Docetaxel 75D1 + Cisplatin 75D1 + 5-FU 750 CI- D1-5 Q 3 weeks x 3 PF: Cisplatin 100 D1 + 5-FU 1000 CI-D1-5 Q 3 weeks x 3
Calais, ASCO, 2006
Surgery
No Response
TPF (n=108)PF (n=112)
P (Log-rank test) = 0.036
0 6 12 18 24 30 36 420
20
40
60
80
100
Per
cent
(%)
Laryngectomy Free Survival (European Definition) (Months)
GORTEC Phase III Larynx Preservation Trial: GORTEC Phase III Larynx Preservation Trial: TPF TPF vsvs PF Induction Therapy for Operable PF Induction Therapy for Operable
Hypopharynx and LarynxHypopharynx and Larynx
Calais et al. ASCO, 2006. Oral Presentation.Calais et al. ASCO, 2006. Oral Presentation.LFS = Improved LRC
TPFTPF PFPF PPNumberNumber 9090 7676HypopharynxHypopharynx 43 (48%)43 (48%) 34 (45%)34 (45%)LarynxLarynx 47 (52%)47 (52%) 42 (55%)42 (55%)Median Age (Range)Median Age (Range) 56 (3956 (39--82)82) 59 (3759 (37--80)80) P=.21P=.21Operability UnresectableOperability Unresectable
Low CurabilityLow CurabilityPreservationPreservation
““OperableOperable””
23 (26%) 23 (26%) 22 (24%)22 (24%)45 (50%)45 (50%)67 (74%)67 (74%)
20 (26%)20 (26%)16 (21%)16 (21%)40 (53%)40 (53%)56 (74%)56 (74%)
P=.90P=.90
T Stage T1,T2 T Stage T1,T2 T3 T3 T4 T4
15 (17%)15 (17%)35 (39%)35 (39%)40 (44%)40 (44%)
17 (22%)17 (22%)33 (43%)33 (43%)26 (34%)26 (34%)
P=.37P=.37
Nodal Stage N0,N1 Nodal Stage N0,N1 N2 N2 N3 N3
43 (47%)43 (47%)35 (39%)35 (39%)12 (13%)12 (13%)
33 (46%)33 (46%)31 (40%)31 (40%)12 (15%)12 (15%)
P=.81P=.81
Clinical Stage III Clinical Stage III IV IV
22 (24%)22 (24%)68 (76%)68 (76%)
22 (29%)22 (29%)54 (71%)54 (71%)
P= .60P= .60
Characteristics of Hypopharynx and Characteristics of Hypopharynx and Larynx Cases Treated On TAX324Larynx Cases Treated On TAX324
TPFTPF PFPF PPNumberNumber 9090 7676 166166Overall SurvivalOverall Survival
Median, mo (range)Median, mo (range)2 Year2 Year3 Year3 YearHazard ratioHazard ratio
59 (3159 (31--NR) NR) 64% (5464% (54--74%)74%)57% (4657% (46--68%)68%)
24 (1324 (13--42)42)50% (3850% (38--61%)61%)40% (2940% (29--52%)52%)
0.62 (0.410.62 (0.41--0.94)0.94) .024.024PFS ( Equivalent to LFS)PFS ( Equivalent to LFS)
Median, mo (range)Median, mo (range)2 Year2 Year3 Year3 YearHazard ratioHazard ratio
21 (1221 (12--59)59)48% (3748% (37--58%)58%)43% (3243% (32--54%)54%)
11 (811 (8--14)14)33% (2233% (22--43%)43%)29% (1929% (19--40%)40%)
.66 (0.45.66 (0.45--0.97)0.97) .032.032
Larynx and Hypopharynx Survival Larynx and Hypopharynx Survival and Progression Free Survival and Progression Free Survival
Hazard Ratio 0.62 (0.41-0.94) P = .024
Larynx and Hypopharynx Overall SurvivalLarynx and Hypopharynx Overall Survival
TPFTPF PFPF PPNumberNumber 6767 5656 123123Overall SurvivalOverall Survival
Median MonthsMedian Months2 Year2 Year3 Year3 YearHazard RatioHazard Ratio
71 (3271 (32--NR) NR) 67% (5667% (56--79%)79%)58% (4658% (46--71%)71%)
27 (1827 (18--NR)NR)53% (4053% (40--66%)66%)47% (3447% (34--60%)60%)
0.67 (0.410.67 (0.41--1.11)1.11) P=0.12P=0.12PFS ( Equivalent to LFS)PFS ( Equivalent to LFS)
Median MonthsMedian Months2 Year2 Year3 Year3 YearHazard RatioHazard Ratio
21 (1221 (12--NR)NR)50% (3750% (37--62%)62%)48% (3548% (35--60%)60%)
12 (812 (8--15)15)34% (2134% (21--46%)46%)32% (1932% (19--44%)44%)
0.61 (0.3950.61 (0.395--0.96)0.96) P = .033P = .033
Results in Results in ““OperableOperable”” Hypopharynx Hypopharynx and Larynx Patients and Larynx Patients –– OS and PFSOS and PFS
TPFTPF PFPF PPNumberNumber 6767 5656 123123Overall LFSOverall LFS
Median MonthsMedian Months2 Year2 Year3 Year3 YearHazard RatioHazard Ratio
39 (1739 (17--NR) NR) 58% (4658% (46--70%)70%)52% (3952% (39--65%)65%)
18 (1018 (10--24)24)37% (2437% (24--50%)50%)32% (1932% (19--45%)45%)
0.59 (0.370.59 (0.37--0.95)0.95) P=0.03P=0.03
Results in Results in ““OperableOperable”” Hypopharynx Hypopharynx and Larynx Patients and Larynx Patients –– LFS*LFS*
*Alive *Alive –– No Primary Site SurgeryNo Primary Site Surgery
LFS in the Operable Patient PopulationLFS in the Operable Patient Population
Hazard Ratio 0.59 (0.37-0.95) P = .03
Experience With DocetaxelExperience With Docetaxel--Based Based InductionInduction in Locally Advanced SCCHNin Locally Advanced SCCHN
StudyStudy N (Criteria)N (Criteria) Primary Primary EndpointEndpoint RegimensRegimens ResultResult
Vermorken 2007 Vermorken 2007 (EORTC 24791/ (EORTC 24791/ TAX 323)TAX 323)
358 358 (Inoperable)(Inoperable)
PFSPFS PF PF →→RT RT vsvsTPF TPF →→RT RT
TPF led to TPF led to higher PFS and higher PFS and
OS (P <.01)OS (P <.01)Posner, 2007Posner, 2007(TAX 324)(TAX 324)
501 501 (Advanced)(Advanced)
OSOS PF PF →→CRT CRT vsvs
TPF TPF →→CRT CRT
TPF improved TPF improved OS at 3OS at 3--yearsyears
P (<.01)P (<.01)Calais 2006* Calais 2006* (GORTEC 2000(GORTEC 2000--01)01)
213 213 (Resectable)(Resectable)
LxPLxP PF PF vsvsTPF TPF
TPF led to TPF led to higher LxP, CRhigher LxP, CR
*Preliminary results.
All Trials Showed That TPF Had All Trials Showed That TPF Had Less Significant Toxicity Less Significant Toxicity No Effect On Ability To Undergo Sequential CRT Or RT No Effect On Ability To Undergo Sequential CRT Or RT
Improved Local Regional Control Improved Local Regional Control
Sequential Therapy: The DataSequential Therapy: The Data
Sequential Therapy with TPF is a Standard of Care for Locally Sequential Therapy with TPF is a Standard of Care for Locally Advanced SCCHN Advanced SCCHN –– It is FDA ApprovedIt is FDA ApprovedTPF and Sequential TPF Significantly Improve Survival and TPF and Sequential TPF Significantly Improve Survival and Organ Preservation Compared to PF Organ Preservation Compared to PF
EvidenceEvidence From Randomized Trials Supports CRT and PFFrom Randomized Trials Supports CRT and PF--Induction Chemotherapy as at Least Equivalent for Survival and Induction Chemotherapy as at Least Equivalent for Survival and SafetySafety–– There is Evidence Suggesting that PF Induction Chemotherapy MighThere is Evidence Suggesting that PF Induction Chemotherapy Might t
be Safer than CRTbe Safer than CRT–– There is Evidence Suggesting TPFThere is Evidence Suggesting TPF--Based Sequential Therapy Might be Based Sequential Therapy Might be
Better and Safer than CRT aloneBetter and Safer than CRT alone–– Phase III Trials Will Compare TPFPhase III Trials Will Compare TPF--Based Sequential Therapy to Based Sequential Therapy to
ChemoradiotherapyChemoradiotherapy
Forastiere, 2006; Taylor, 1996Forastiere, 2006; Taylor, 1996
*Vermorken, 2007:Posner, 2007; Calais, 2006*Vermorken, 2007:Posner, 2007; Calais, 2006
Induction PF Induction PF vsvs PFPF--CRT for CRT for Unresectable Head and Neck Cancer Unresectable Head and Neck Cancer
PFPF PFPF--CRTCRTTotal TreatedTotal Treated 100100 9494Dead of DiseaseDead of Disease 5959 4444Died on TherapyDied on Therapy 66 1111Died of Toxicity*Died of Toxicity* 77 1515Total AliveTotal Alive 28 (28%)28 (28%) 24 (26%) 24 (26%)
*Pulmonary, Bleeding*Pulmonary, BleedingTaylor, JCO, 1996
PFPF--Based Concurrent CRT:Based Concurrent CRT:Duke Randomized Phase II PaliferminDuke Randomized Phase II Palifermin
PaliferminPalifermin Control Control TotalTotalNumber EnteredNumber Entered 6969 3232 101101Discontinued NonDiscontinued Non--ToxicToxic 1111 22 1313TreatedTreated 5858 3030 8888DeathsDeaths (20 wk Study Period) 4 (7%) 2 (7%)(20 wk Study Period) 4 (7%) 2 (7%) 6(7%)6(7%)ITT (%) ITT (%) (6%)(6%) (6%)(6%) (6%)(6%)
CisplatinCisplatin
RADIOTHERAPYRADIOTHERAPYQD or BIDQD or BID
++ PaliferminPalifermin
55--FUFU
Brizel, JCO, 2008
Induction Chemotherapy, Sequential Therapy Induction Chemotherapy, Sequential Therapy and Chemoradiotherapy and Chemoradiotherapy –– LogicLogic and Bioand BioLogicLogic
PFPF--Based Induction Chemotherapy and Chemoradiotherapy Based Induction Chemotherapy and Chemoradiotherapy SignificantlySignificantly Improve Survival and Organ Preservation Improve Survival and Organ Preservation Compared to Radiotherapy +/Compared to Radiotherapy +/-- SurgerySurgeryPFPF--Based Induction Chemotherapy and Chemoradiotherapy Based Induction Chemotherapy and Chemoradiotherapy are are EquivalentEquivalent for Survival and Organ Preservation (LFS)*for Survival and Organ Preservation (LFS)*TPFTPF--Based Induction Chemotherapy is Based Induction Chemotherapy is SignificantlySignificantly Better Better than PF for Survival and Organ Preservation (LFS)than PF for Survival and Organ Preservation (LFS)TPFTPF--Based Induction Chemotherapy Might be Better Based Induction Chemotherapy Might be Better ththananChemoradiotherapy for Survival and Organ PreservationChemoradiotherapy for Survival and Organ Preservation
*Taylor, 1996; Forastiere, 2006; Lefebvre, 2007
Sequential Therapy: The FutureSequential Therapy: The Future
Sequential Therapy with TPF and CRT is a Standard of Care for Sequential Therapy with TPF and CRT is a Standard of Care for Locally Advanced SCCHN in the USLocally Advanced SCCHN in the US–– Sequential Therapy With TPF is Tolerable and SafeSequential Therapy With TPF is Tolerable and Safe–– Sequential Therapy Makes Biological Sense and is Highly EffectivSequential Therapy Makes Biological Sense and is Highly Effective e –– Phase III Trials Will Compare TPFPhase III Trials Will Compare TPF--Based Sequential Therapy to Based Sequential Therapy to
ChemoradiotherapyChemoradiotherapy
TPFTPF--Based Sequential Therapy is Platform For Exploiting New Based Sequential Therapy is Platform For Exploiting New Targeted TherapiesTargeted Therapies–– Improving Induction Chemotherapy and ChemoradiotherapyImproving Induction Chemotherapy and Chemoradiotherapy–– Reducing Morbidity and MortalityReducing Morbidity and Mortality
Sequential Therapy: The FutureSequential Therapy: The Future
Induction ChemotherapyInduction Chemotherapy–– High Response Rates, Organ Preservation, Improved Survival, SystHigh Response Rates, Organ Preservation, Improved Survival, Systemic emic
TreatmentTreatment–– Reduced Tumor Volume, Better IMRT Planning, Improved FunctionReduced Tumor Volume, Better IMRT Planning, Improved Function–– An Intermediate Assessment of ResponseAn Intermediate Assessment of Response
ChemoradiotherapyChemoradiotherapy–– RiskRisk--Based Based -- Response to Induction Therapy/ Potential Response to Induction Therapy/ Potential
Toxicity/Prognostic Factors/Planned SurgeryToxicity/Prognostic Factors/Planned Surgery–– Increased/Decreased Dose Intensity, New Biologics, Improved IMRTIncreased/Decreased Dose Intensity, New Biologics, Improved IMRT
PlanningPlanningSurgerySurgery–– Remove Areas of Initial Bulk DiseaseRemove Areas of Initial Bulk Disease–– Preserve Primary SitePreserve Primary Site
Sequential Combined Modality TherapySequential Combined Modality TherapyA Phase III Study: TPF A Phase III Study: TPF vsvs PF Followed by PF Followed by
ChemoradiotherapyChemoradiotherapy vsvs CRTCRT
RANDOMIZE
P
P
F
F
Cisplatinum 100 mg/M2
Daily Radiotherapy
T
Salvage Surgery
TPF: Taxotere 75D1 + Cisplatin 75D1 + 5-FU 750 CI-D1-5 Q 3 weeks x3 PF: Cisplatin 100 D1 + 5-FU 1000 CI-D1-5 Q 3 weeks x 3
CRT: Cisplatin 100 D1,22,42; Hitt et al, ASCO, 2006
HearHear No InductionNo Induction
SeeSee No InductionNo Induction
SpeakSpeak No InductionNo Induction
HearHear About The Data About The Data
ThinkThink About The DataAbout The Data
SpeakSpeak About The DataAbout The Data
Evaluate the Data:Evaluate the Data:Form Your Own Form Your Own
OpinionOpinion
Question
Group ACetuximab 400 mg/m2 initial dose
then 250 mg/m2 weekly +EITHER carboplatin (AUC 5, d1) OR cisplatin (100 mg/m2 IV, d1)+ 5-FU (1000 mg/m2 IV, d1-4):
3-week cycles
Group BEITHER carboplatin (AUC 5, d1) OR cisplatin (100 mg/m2 IV, d1) + 5-FU (1000 mg/m2 IV, d1-4):
3-week cycles
No treatmentCetuximab
Randomized
Progressive disease or unacceptable toxicity
6 chemotherapy cycles maximum
The EXTREME TrialThe EXTREME Trial
Patients at Risk Survival Time [Months]CTX onlyCET + CTX
220 173 127 83 65 47 19 8 1222 184 153 118 82 57 30 15 3
HR (95%CI): 0.797 (0.644, 0.986)Strat. log-rank test: 0.0362
Overall SurvivalCTX onlyCET + CTX
Sur
viva
l Pro
babi
lity
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 3 6 9 12 15 18 21 24
|| |
| |
| |
||| | || ||| || |||| | | |||| | | | | ||| | | | | | | ||
| |
| |
|
|
|
||
||| | | |||| ||| ||| || | | || | | || | ||| | | | | ||| | | ||| | |
10.1 momo
7.4 mo
~10%~10%
Induction Chemotherapy: Weekly Paclitaxel, Induction Chemotherapy: Weekly Paclitaxel, Carboplatin, and Cetuximab Carboplatin, and Cetuximab –– PCPC22
CarboplatinCarboplatin
Taxol Taxol
C225 C225
WEEKLY CHEMOTHERAPY:WEEKLY CHEMOTHERAPY:C225 400mg/m2 wk1 C225 400mg/m2 wk1 -- 250mg/m2 wk 2250mg/m2 wk 2--66
Paclitaxel 135 mg/m2 wk 1Paclitaxel 135 mg/m2 wk 1--66Carboplatin AUC 2.0 wk 1Carboplatin AUC 2.0 wk 1--66
Early Stage Early Stage –– RadiotherapyRadiotherapy
Advanced Stage Advanced Stage –– ChemoradiotherapyChemoradiotherapy
PRIMARY END POINT: PRIMARY END POINT:
Safety, Tolerability, Response Safety, Tolerability, Response
Kies et al, ASCO, 2006
The DFCI The DFCI TPFTPF--EE Phase I Trial:Phase I Trial:Sequential Therapy with Erbitux Sequential Therapy with Erbitux
P
F
PlatinumPlatinum--based based ChemoradiotherapyChemoradiotherapy
3 Cycles of 3 Cycles of ChemotherapyChemotherapy
T
E Primary End Points: MTD of 5Primary End Points: MTD of 5--FU, SafetyFU, SafetySecondary End Points: Response Rate, PFSSecondary End Points: Response Rate, PFS
Taxotere 75 mg/MTaxotere 75 mg/M22; Cisplatin 100 mg/M; Cisplatin 100 mg/M22; 5; 5--FU 700FU 700--1000 mg/M1000 mg/M22/day for 4 days/day for 4 days
Erbitux 400/250 mg/MErbitux 400/250 mg/M22 weeklyweekly
RTOG 0522: A Randomized Phase III Trial of RTOG 0522: A Randomized Phase III Trial of ACB Chemoradiotherapy With or Without ACB Chemoradiotherapy With or Without
CetuximabCetuximab
RANDOMIZE
P - 100 mg/M2
XRT
XRT
C225 400/250 mg
P - 100 mg/M2
Stratify: XRT as Standardor IMRT on DAHANCA
A Growing EpidemicA Growing EpidemicA Therapeutic TargetA Therapeutic Target
Human PapillomavirusHuman Papillomavirusand Oropharyngeal Cancer:and Oropharyngeal Cancer:
A Major Prognostic FactorA Major Prognostic Factor
Oropharynx Cancer and HPVOropharynx Cancer and HPV--20092009New Population At RiskNew Population At Risk–– Increasing NumbersIncreasing Numbers
»» 2525--50% Of New Cases50% Of New CasesOropharynx Oropharynx –– Base of Tongue and Tonsil, Unknown PrimaryBase of Tongue and Tonsil, Unknown PrimaryAdvanced Stage At DiagnosisAdvanced Stage At Diagnosis
–– Sexually TransmittedSexually Transmitted»» Younger, Less Alcohol, Less Tobacco, Both SexesYounger, Less Alcohol, Less Tobacco, Both Sexes
–– Vaccine Available Vaccine Available –– Preventive not TherapeuticPreventive not Therapeutic»» HPV 16, 18, 31, 33HPV 16, 18, 31, 33
–– Different Prognosis Different Prognosis (Responsive (Responsive vsvs Aggressive)Aggressive)»» More Responsive To Radiotherapy?, Chemotherapy?More Responsive To Radiotherapy?, Chemotherapy?»» Aggressive Behavior Aggressive Behavior –– High Rate of Distant High Rate of Distant
Metastases in Locally Advanced Disease Metastases in Locally Advanced Disease
HPV and Tonsillar Cancer HPV and Tonsillar Cancer –– Tonsillar Cancer Tonsillar Cancer Sweden and StockholmSweden and Stockholm
0
0,5
1
1,5
2
2,5
3
1970-1979 1980-1989 1990-1999 2000-2002Calender years
Inci
denc
e ra
te (1
/100
000
)
Men Women
2.8 Fold Increase2.8 Fold Increase2.0 Fold Increase2.0 Fold IncreaseDahlstrand ASCO, 2008Dahlstrand ASCO, 2008
Sexual Behaviors And Head And Sexual Behaviors And Head And Neck CancerNeck Cancer
BehaviorBehaviorDiagnosis Of Diagnosis Of HPVHPV--HNSCCHNSCC(Case(Case--case)case)
Risk Of Risk Of HPVHPV--HNSCC HNSCC
(Case(Case--control)control)Number Of Sexual PartnersNumber Of Sexual Partners ++ ++History Of OralHistory Of Oral--Genital SexGenital Sex ++ ++History Of Anal CancerHistory Of Anal Cancer ++ ++Spouse With Tonsil CancerSpouse With Tonsil Cancer ++ ++Cervical CIS or Cancer Cervical CIS or Cancer AssocAssoc AssocAssoc
Ritchie Int J Cancer 2003; Smith EM Int J Cancer 2004; Herrero R JNCI 2003; Rajkumar Eur J Cancer Prev 2003, D’Souza, NEJM, 2007, Hemminiki. IJC 2001
Sequential Therapy forSequential Therapy forLocally Advanced Oropharynx and Larynx Cancer Locally Advanced Oropharynx and Larynx Cancer
ECOG 2399ECOG 2399
Taxol Taxol Weekly Weekly
Cmelak, JCO, 2007
Taxol Taxol Carboplatin Carboplatin
Daily Daily Radiotherapy Radiotherapy
ECOG 2399: HPV ResultsECOG 2399: HPV Results
HPV +*HPV +* HPV HPV --
OPOP 3838 2424
LarynxLarynx 00 3434
TotalTotal 38 (40%)38 (40%) 58 (60%)58 (60%)
* Determined by in situ hybridization for HPV serotype 16, 31, 33, 35
60% of OP Cases Are HPV+ and Almost all are HPV 1660% of OP Cases Are HPV+ and Almost all are HPV 16Cmelak, JCO, 2007
Oropharynx Tumor HPV Status And Oropharynx Tumor HPV Status And SurvivalSurvival
Time in Months
Prob
abili
ty
0 10 20 30 40 50 60
0.0
0.2
0.4
0.6
0.8
1.0
NegativePositive
Log-rank test, p=0.004
Two-year Overall Survival
Fakhry, JNCI, 2008
ECOG 2399: HPV ResultsECOG 2399: HPV Results
HPV +HPV + HPV HPV --
NumberNumber 3838 2424
ProgressionProgressionLRFLRFDMDM
5 (13%)5 (13%)2 (5%)2 (5%)3 (8%)*3 (8%)*
9 (38%)9 (38%)8 (33%)8 (33%)1 (4%)*1 (4%)*
DeathsDeaths 7 (18%)7 (18%) 12 (50%)12 (50%)
Fakhry, JNCI, 2008
* 60% and 11% of Failures, Respectively* 60% and 11% of Failures, Respectively
Oropharynx Cancer and HPVOropharynx Cancer and HPV--20092009How Do We Treat HPV+ Oropharynx CancerHow Do We Treat HPV+ Oropharynx Cancer
HPV has Significant Prognostic Value HPV has Significant Prognostic Value –– HPV+ Oropharynx Cancer is More Responsive to TreatmentHPV+ Oropharynx Cancer is More Responsive to Treatment
»» Is HPV+ Oropharynx Cancer Less Aggressive?Is HPV+ Oropharynx Cancer Less Aggressive?–– In ECOG 2399 Survival in the HPV+ Population is >80%In ECOG 2399 Survival in the HPV+ Population is >80%
»» Early Follow upEarly Follow up»» Aggressive Sequential Therapy Aggressive Sequential Therapy »» Better PS, Age, CoBetter PS, Age, Co--MorbiditiesMorbidities
–– Retrospective/Prospective Analysis of Phase III Trials is OngoinRetrospective/Prospective Analysis of Phase III Trials is Ongoingg»» RTOG 01RTOG 01--29, Tax 324, RTOG 0529, Tax 324, RTOG 05--2222
Do Not Change Practice Yet!Do Not Change Practice Yet!–– Treat HPV Positive Oropharynx Cancer As You HaveTreat HPV Positive Oropharynx Cancer As You Have
»» Are We Happy With 80% Survival?Are We Happy With 80% Survival?»» Where Do People Fail?Where Do People Fail?»» What Can We Reduce What Can We Reduce –– Chemotherapy, Radiotherapy?Chemotherapy, Radiotherapy?
Head and Neck Cancer and HPVHead and Neck Cancer and HPVTough Questions Will Be Addressed To Tough Questions Will Be Addressed To CliniciansClinicians–– PatientPatient
»» Am I At Risk For A Second CancerAm I At Risk For A Second Cancer»» How Long Have I Had ThisHow Long Have I Had This»» How Did I Get ItHow Did I Get It
–– SpouseSpouse»» Should I Get VaccinatedShould I Get Vaccinated»» Do I Need SurveillanceDo I Need Surveillance»» What Is My RiskWhat Is My Risk
–– ChildrenChildren»» Are They At Risk?Are They At Risk?
Oropharynx Cancer and HPVOropharynx Cancer and HPV--20092009A Major Opportunity for Specific TherapyA Major Opportunity for Specific Therapy
HPVHPV is a Specific Tumor Target is a Specific Tumor Target –– E6 and E7 Viral Oncogenes Necessary for Tumor Cell SurvivalE6 and E7 Viral Oncogenes Necessary for Tumor Cell Survival–– Foreign Antigen or Genetic TargetForeign Antigen or Genetic Target–– Only Present in Infected CellsOnly Present in Infected Cells
This Disease Could be the Poster Child for Targeted This Disease Could be the Poster Child for Targeted Therapy and ImmunotherapyTherapy and Immunotherapy–– Prevention Prevention –– Risk Identification/VaccineRisk Identification/Vaccine–– Treatment Treatment –– Advanced/Incurable; New Diagnosis, AdjuvantAdvanced/Incurable; New Diagnosis, Adjuvant–– Targeting E6 and E7 Targeting E6 and E7 –– Necessary for Tumor Cell SurvivalNecessary for Tumor Cell Survival
»» Therapeutic Vaccines, siRNA, SMIs, AntiTherapeutic Vaccines, siRNA, SMIs, Anti--SenseSenseScientific OpportunitiesScientific Opportunities–– Pathogenesis, LatencyPathogenesis, Latency–– Susceptibility, Immunity, ImmunosuppressionSusceptibility, Immunity, Immunosuppression
This Disease Should be a Major Priority for NCI FundingThis Disease Should be a Major Priority for NCI Funding–– More Cases Than Advanced MelanomaMore Cases Than Advanced Melanoma
Oropharynx Cancer and HPVOropharynx Cancer and HPV--20092009A Major Opportunity for Specific TherapyA Major Opportunity for Specific Therapy
HPV HPV Positive Oropharyngeal Cancer Positive Oropharyngeal Cancer
–– Is Preventable in the Next GenerationIs Preventable in the Next Generation»» Should We Vaccinate All Adolescents and Young Adults Should We Vaccinate All Adolescents and Young Adults
(20(20--40 yrs)?40 yrs)?
–– Should be Curable Without Chemotherapy or Should be Curable Without Chemotherapy or Radiotherapy Within the Next 5 YearsRadiotherapy Within the Next 5 Years
»» We Need Research FundingWe Need Research Funding
The Role of the Surgical Oncologist in The Role of the Surgical Oncologist in Head and Neck Cancer Head and Neck Cancer
For years: the only optionFor years: the only option……
“The most radical operation, done as soon as possible, to eradicate the last living cancer cell in the surgical
field…”
- Sir William HalstedJohns Hopkins University